All Stories

  1. ERN ReCONNET–SLICC–SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2)
  2. Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA network registry
  3. Translating cardiorheumatology into practice: a multilevel pilot network
  4. Association between canakinumab dose and long-term remission in Still’s disease: insights from the AIDA network registry
  5. International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study
  6. Global author collaborations in lupus research and publications: a meta-research and network analysis
  7. Ophthalmic involvement in VEXAS syndrome and its influence on mortality: insights from the international AIDA network registry
  8. Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study
  9. Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry
  10. The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease–related spondyloarthritis: insights from a cross-sectional study
  11. The Italian Society of Rheumatology clinical practice guidelines for the management of vaccines in adult patients with rheumatic diseases
  12. VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries
  13. Ultrasound-Guided Synovial Biopsy Can Be Effectively and Safely Performed in Different Clinical Settings Favouring a Widespread Application of Precision Medicine in Rheumatoid Arthritis: A Post-hoc Analysis of Three Clinical Trials
  14. Recurrent fever and association with severe organ involvement, mortality and treatment outcomes in VEXAS syndrome: data from the AIDA Network
  15. Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study
  16. Ultrasound for assessing disease activity and structural damage in psoriatic arthritis: the UPsA scores from a multicentre study by the Italian Society of Rheumatology
  17. The use of non-TNF targeted biologics in Behçet’s disease: real-life data from the International AIDA Network Behçet’s Disease Registry
  18. Machine Learning for MRI Classification of Systemic Lupus Erythematous Patients with and without Neuropsychiatric Events
  19. Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review
  20. Reproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry
  21. Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries
  22. Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort
  23. The metabolomic profile of psoriatic arthritis patients unveils the unbalance of disease-related molecules and pathways
  24. International development and validation of a multilingual bank of items for the self-assessment of essential knowledge by lupus patients: the SLE Knowledge Assessment Score (SLAKE)
  25. The impact of demographics on organ damage in Behçet’s syndrome: a cross-sectional analysis of the international PROBE cohort
  26. Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry
  27. The Risk of Developing Ocular Involvement Among Behçet’s Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet’s Disease Registry
  28. Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO study
  29. Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)
  30. Entheseal structural damage according to OMERACT definitions unveils distinct ultrasound phenotypes in SpA: findings from the DEUS multicentre study
  31. Predictors of uveitic macular edema and functional prognostic outcomes: real-life data from the international AIDA Network uveitis registry
  32. The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus
  33. ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations
  34. Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab: a potential biomarker for personalized treatment in systemic lupus erythematosus
  35. Lupus serology: off target but still relevant to the treat-to-target strategy in systemic lupus erythematosus
  36. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force
  37. Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network
  38. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
  39. Disease activity and disability influence CV risk estimation and management of rheumatoid arthritis patients
  40. Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
  41. Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry
  42. Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry
  43. VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management
  44. The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis
  45. Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study
  46. Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus
  47. Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology
  48. Clinical Characteristics of Anti‐Synthetase Syndrome: Analysis From the Classification Criteria for Anti‐Synthetase Syndrome Project
  49. Sex Differences in Cardiovascular Risk Profiles of Patients with Rheumatoid Arthritis: Results from an Italian Multicentre Cohort
  50. Relationship Between Ultrasound and Physical Examination in the Assessment of Enthesitis in Patients With Spondyloarthritis: Results From the DEUS Multicenter Study
  51. Mood Disorder Questionnaire Positivity in Systemic Lupus Erythematosus and Other Chronic Diseases including Screen Bipolar Disorders or Rhythm and Energy Dysregulation Syndromes (DYMERS)
  52. Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study
  53. Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study
  54. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry
  55. Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast
  56. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development
  57. Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders
  58. Structural Brain MR Imaging Alterations in Patients with Systemic Lupus Erythematosus with and without Neuropsychiatric Events
  59. Ocular Manifestations in Juvenile Behçet’s Disease: A Registry-Based Analysis from the AIDA Network
  60. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank
  61. Diagnostic pathway and treatment preferences for systemic lupus erythematosus: a physician-based discrete choice experiment
  62. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study
  63. Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review
  64. Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort
  65. Quality of Life in Systemic Lupus Erythematosus and Other Chronic Diseases: Highlighting the Amplified Impact of Depressive Episodes
  66. Organ damage is a major determinant of work productivity impairment in Behçet’s syndrome: a post hoc analysis of the BODI validation study
  67. Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study
  68. Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease
  69. Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission
  70. Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study
  71. Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry
  72. The Challenging Differentiation of Psoriatic Arthritis from Other Arthropathies and Nonspecific Arthralgias in Patients with Psoriasis: Results of a Cross-Sectional Rheumatologic Assessment of a Large Dermatologic Cohort
  73. Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. The impact of cardiovascular co...
  74. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project
  75. Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus
  76. C-reactive protein level association with future cardiovascular events assessed by different risk scores among rheumatoid arthritis patients
  77. Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
  78. Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group
  79. Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry
  80. Efficacité de l’anakinra dans la polysérite réfractaire : étude multicentrique italienne
  81. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
  82. Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study
  83. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium
  84. C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis
  85. The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases
  86. Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study
  87. Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
  88. Italian recommendations for the assessment of cardiovascular risk in rheumatoid arthritis: a position paper of the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group of the Italian Society of Rheumatology
  89. Development and implementation of the AIDA International Registry for patients with Behçet’s disease
  90. Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome
  91. Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study
  92. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
  93. Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?
  94. Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity
  95. Anakinra effectiveness in refractory polyserositis: An Italian multicenter study
  96. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies
  97. Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group
  98. An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations
  99. Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome
  100. Similarities and differences between younger and older disease onset patients with newly diagnosed systemic lupus erythematosus
  101. Whole-Body MRI in Rheumatology: Major Advances and Future Perspectives
  102. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
  103. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis
  104. Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic
  105. Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis
  106. Targeted Therapies in Axial Psoriatic Arthritis
  107. Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
  108. Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs
  109. Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)
  110. Rheumatoid arthritis: Extra-articular manifestations and comorbidities
  111. Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review
  112. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
  113. Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis
  114. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review
  115. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
  116. Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud’s arthropathy and a distinctive MRI pattern
  117. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network
  118. Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort
  119. Comprehensive arginine metabolomics and peripheral vasodilatory capacity in rheumatoid arthritis: A monocentric cross-sectional study
  120. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties
  121. Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network
  122. Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)
  123. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting
  124. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
  125. Correction to: Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
  126. Methotrexate and Vasculoprotection: Mechanistic Insights and Potential Therapeutic Applications in Old Age
  127. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort
  128. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
  129. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography
  130. Treatment target in newly diagnosed Systemic Lupus Erythematosus
  131. Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçet’s Syndrome
  132. The rs75862629 minor allele in the endoplasmic reticulum aminopeptidases intergenic region affects human leucocyte antigen B27 expression and protects from ankylosing spondylitis in Sardinia
  133. SAT0035 IS PHARMACOLOGICAL CLINICAL REMISSION SYNONYMOUS WITH BIOLOGICAL INACTIVE DISEASE? DIFFERENTIAL GENE EXPRESSION ANALYSIS IN RHEUMATOID ARTHRITISAND HEALTY CONTROLS
  134. Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECRS1.0
  135. Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response
  136. First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry)
  137. Rheumatoid Arthritis: Atherosclerosis Imaging and Cardiovascular Risk Assessment Using Machine and Deep Learning–Based Tissue Characterization
  138. Nonlinear model for the carotid artery disease 10‐year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: A Japanese diabetes cohort study
  139. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria
  140. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
  141. Ultrasonography in psoriatic arthritis: which sites should we scan?
  142. AIF-1 gene does not confer susceptibility to Behçet’s disease: Analysis of extended haplotypes in Sardinian population
  143. The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the ...
  144. An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes
  145. Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis
  146. Clinical and ultrasonographic predictors for achieving minimal disease activity in patients with psoriatic arthritis: the UPSTREAM (Ultrasound in PSoriatic arthritis TREAtMent) prospective observational study protocol
  147. Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study
  148. Polymyalgia rheumatica: an autoinflammatory disorder?
  149. Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset
  150. Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study
  151. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
  152. Atherosclerosis and Autoimmunity
  153. Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series
  154. Re: “Ultrasound Findings on Hands and Wrists of Patients with Systemic Lupus Erythematosus: Relationship with Physical Examination”
  155. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus
  156. Rituximab is a valid alternative to standard of care in severe inflammatory neuropsychiatric lupus.
  157. Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease
  158. Telemedicine for patients with rheumatic diseases: Systematic review and proposal for research agenda
  159. Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus
  160. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
  161. Overexpression of the Cytokine BAFF and Autoimmunity Risk
  162. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis
  163. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence
  164. Pachydermopériostose, un cas d’épanchement articulaire volumineux avec atteinte polyarticulaire imitant l’arthrite juvénile idiopathique
  165. Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography
  166. Predictors of musculoskeletal flares and Jaccoud׳s arthropathy in patients with systemic lupus erythematosus: A 5-year prospective study
  167. Hand tele-rehabilitation system
  168. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review
  169. Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology
  170. Pachidermoperiostosis as a cause of massive joint effusion with polyarticular involvement mimicking juvenile idiopathic arthritis: A case report
  171. The Ankylosing Spondylitis-Associated HLA-B*2705 Presents a B*0702-Restricted EBV Epitope and Sustains the Clonal Amplification of Cytotoxic T Cells in Patients
  172. The Difficult Task of Assessing Psoriatic Arthritis
  173. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol
  174. Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
  175. Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012
  176. Epidemiology of systemic lupus erythematosus in Sardinia.
  177. Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement
  178. Early Lupus Project – A multicentre Italian study on systemic lupus erythematosus of recent onset
  179. Killer-Cell Immunoglobulin-Like Receptors (KIR) and HLA-Class I Heavy Chains in Ankylosing Spondylitis
  180. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus
  181. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort
  182. Clinical potential of apremilast in the treatment of psoriatic arthritis
  183. Telemedicine Applied to Kinesiotherapy for Hand Dysfunction in Patients with Systemic Sclerosis and Rheumatoid Arthritis: Recovery of Movement and Telemonitoring Technology
  184. A Device for Local or Remote Monitoring of Hand Rehabilitation Sessions for Rheumatic Patients
  185. Section 2: Spondyloarthritis
  186. The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09
  187. Rituximab treatment for ‘rhupus syndrome’: clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study
  188. An Integrated Portable Device for the Hand Functional Assessment in the Clinical Practice
  189. Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests
  190. Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients
  191. Myocardial Positron Emission Tomography/Computed Tomography Scan Revealing Right Coronary Artery Involvement in Large Vessel Vasculitis
  192. Susceptibility to ankylosing spondylitis but not disease outcome is influenced by the level of HLA-B27 expression, which shows moderate variability over time
  193. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients
  194. Managing CNS involvement in systemic lupus erythematosus
  195. Two different clinical subsets of lupus hepatitis exist. Mimicking primary autoimmune liver diseases or part of their spectrum?
  196. GENETICS OF PSORIASIS AND PSORIATIC ARTHRITIS
  197. Post-Streptococcal Reactive Arthritis Associated With Group G Streptococcal Pharyngitis
  198. Genetic susceptibility to Behcet's disease: role of genes belonging to the MHC region
  199. Coronary atherosclerosis using computed tomography coronary angiography in patients with systemic sclerosis: comment on the article by Mok et al
  200. Multiple Septic Bursitis and Spontaneous Achilles Tendon Tear in Systemic Lupus Erythematosus
  201. Defective cerebral gamma-aminobutyric acid-A receptor density in patients with systemic lupus erythematosus and central nervous system involvement. An observational study
  202. Familial chilblain and late contractural arachnodactyly: A novel association?
  203. Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission